Yang, L. and Ma, A. (2023) “Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation”, Frontiers in Business, Economics and Management, 8(3), pp. 178–184. doi:10.54097/fbem.v8i3.7835.